20251130-华鑫证券-医药行业周报_关注吸入制剂在呼吸疾病领域的突破_31页_1mb

Pharmaceutical Industry Weekly Summary: Focus on Inhalable Formulations and Breakthroughs

Key Industry Insights

• Inhalable Formulations in Respiratory Diseases: Recent advancements in treatments like TPIP (for pulmonary arterial hypertension) and acquisitions by Merck & Co. (e.g., Verona Pharma) highlight improved efficacy and global interest. Domestic companies are overcoming technical barriers, positioning for international expansion due to patent protections. This area shows potential for innovation and out-of-China development.
• Exosomal Small Nucleic Acid Therapies: Arrowhead Pharmaceuticals achieved milestones with ARO-DM1, targeting Duchenne muscular dystrophy. While still in early stages, the TRiM™ platform for liver-extraneous targeting offers broad therapeutic potential, with ALN-based comparisons ongoing.
• Influenza Outbreak and Drugs: Flu positivity rates are rising, peaking above 40%. New antiviral drugs (e.g., from Roche, Zongsheng) have been approved, with concerns over drug resistance. Increased detection and sales channels are boosting market demand, influenced by guidelines and pricing policies.
• Diabetes Treatments: GLP-1 receptor agonists like Amycretin demonstrate strong weight loss and glycemic control. Differentiation (e.g., dual-target combinations) is key for market success, amid US price reductions and European regulatory focus on novel mechanisms.
• Raw Material Price Cycles: Prices vary by supply-demand dynamics; raw materials like amoxicillin and vitamin E saw high valuations, while VC (carbon suboxide) recently surged due to anti-idle competition. Stable competition and demand growth could sustain high profitability.

Investment and Selection Recommendations

• Focus Areas: Prioritize inhalable preparations (e.g., Changfeng Pharmaceutical), exosomal therapies (companies like Yuekang and Yangguangnohe), flu drugs (Zongsheng and Innoter), raw material cycles (Fuxiang Yafarm and Sutili), and emerging tech in healthcare (Xiangyuming and Bianqixi).
• Recommended Companies:
  • Longfeng Pharmaceutical, Yuekang Pharmaceutical, Yangguangnohe, Zongsheng Pharmaceutical, Innoter, ayzhemu.
  • Stocks with positive earnings forecasts include several listed firms, avoiding those with negative outlooks.
  • Diversify across sectors: biopharma collaborations (e.g., Baiying Medical) and high-value medical exports (Chengli Medical, Cangnan Medical).

Risk Considerations

• High R&D failure risk, sales uncertainties due to market adaptation, increased competition from multiple product launches, and regulatory shifts within the pharmaceutical sector. Always monitor policy changes and clinical progressions.

Overall Outlook

The industry shows strong innovation potential, driven by technological advancements and global expansion. Timing is crucial for investments, especially in volatile markets, with a focus on differentiation and market access strategies.

Please refer to the full report for detailed data and disclosures.